Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 7, 2013; 19(5): 721-726
Published online Feb 7, 2013. doi: 10.3748/wjg.v19.i5.721
Published online Feb 7, 2013. doi: 10.3748/wjg.v19.i5.721
Table 1 Baseline demographics (n = 163) n (%)
Age (yr) | |
Mean age | 52.0 (24-86) |
Mean age at start | 47.4 (20-81) |
Gender | |
Males | 113 (69.3) |
Females | 50 (30.7) |
Pre-treatment Biopsies | 134 (82.2) |
Duration of therapy (mo) | |
Range | 3-46 |
Mean | 25.63 |
Median | 23 |
Patients > 24 mo | 79 (48.5) |
Patients > 36 mo | 49 (30.1) |
Co-infection | |
Hepatitis C | 1 (0.61) |
HBV DNA load (IU/mL) | |
> 100 000 | 95 (58.3) |
2000-100 000 | 45 (27.6) |
12-2000 | 23 (14.1) |
HBe antigen status | 41 (25.2) |
e antigen positive | 112 (68.7) |
e antigen negative | 10 (6.1) |
Unknown | |
ALT (U/L) | |
10-40 | 39 (23.9) |
40-400 | 118 (72.4) |
> 400 | 5 (3.01) |
Unknown | 1 (0.61) |
Fibrosis score | 0-10 (6.13) |
135 (82.82%) | 1-61 (37. 4) |
2-38 (23.3) | |
3-17 (10.4) | |
4-9 (5.52) | |
Unknown-27 (16.6) |
- Citation: Fahrtash-Bahin F, Kariyawasam VC, Gray T, Byth K, George J, Douglas MW. Australian tertiary care outcomes of entecavir monotherapy in treatment naive patients with chronic hepatitis B. World J Gastroenterol 2013; 19(5): 721-726
- URL: https://www.wjgnet.com/1007-9327/full/v19/i5/721.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i5.721